Sunitinib

Use the mouse wheel or two fingers (on touchscreens) to zoom in and out of the map.

Map view:

Zoom: 100%

More settings

Connection length 100% Label size 100% Node size 100% Line width 100% Label width 100%

Export map as:

Sunitinib topic overview

The analysis highlights History, Community, Culture and Applications as prominent areas in the source structure around Sunitinib.

Related topics: 64
Source areas: 8
Connected nodes: 72
Extracted relationships: 92
Concept neighborhoods: 22
Bridge connections: 72

What this topic covers Research coverage

Source areas are shown by the number of related topics found in each part of the analysis. Use smaller areas too: they can reveal specialized angles and content gaps.

Mechanism of action · 15 topics

Medical uses · 14 topics

Overview · 11 topics

Research · 10 topics

History · 7 topics

Society and culture · 4 topics

Interactions · 2 topics

Side effects · 1 topics

Smaller areas are not necessarily less important. They contain fewer connections in this analysis and can be useful for finding specialized angles or coverage gaps.

Key facts & relationships

High-confidence facts extracted from structured source data. Use them as anchors for further research.

3D model (JSmol): Interactive image
AHFS/Drugs.com: Monograph
ATC code: L01EX01 (WHO)
Bioavailability: Unaffected by food
CAS Number: 557795-19-4 Y · as salt: 341031-54-7 Y
ChEBI: CHEBI:38940 Y

Explore all related topics Closing gaps

Browse the complete topic structure, not only the most central items. Less prominent entities and concepts can reveal missing angles, specialized context and useful research gaps. Each item opens a new analysis centered on that subject.

Overview

Medical uses

Phase III clinical trial Phases of clinical research
Secondary endpoints End point of clinical trials
Statistically significant Statistical significance
Progression-free survival
Objective response Clinical endpoint
Relative risk
Treatment-related adverse event Adverse event
Serious adverse events Serious adverse event
Meningioma
Neurofibromatosis
Aggressive fibromatosis
Neuroendocrine tumors Neuroendocrine tumor
Metastatic Metastasis
Interferon alpha Alpha-interferon

Mechanism of action

Receptors Receptor (biochemistry)
Platelet-derived growth factor
PDGF-Rs PDGF-R
Vascular endothelial growth factor
VEGFRs
Angiogenesis
Tumor vascularization Vasculogenic mimicry
Apoptosis
CD117
RET RET proto-oncogene
CD114
CD135
Hand-foot syndrome
Stomatitis
Dermatologic Dermatology

History

SUGEN
Protein kinase inhibitors. Protein kinase inhibitor
SU5416 Semaxanib
ATP Adenosine triphosphate
Tyrosine kinase inhibitors Tyrosine kinase inhibitor
Gleevec
Tarceva

Side effects

Chemotherapy-induced acral erythema

Interactions

Society and culture

Research

Tyrosine kinase
KIT KIT (gene)
PDGFR
VEGFR2
Metastatic breast cancer
Non-small-cell lung cancer
Leukemia
Washington University in St. Louis
Genetic sequencing Whole genome sequencing
FLT3

Advanced semantic analysis

Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.

How Sunitinib connects Entity context

The extracted context around Sunitinib shows recurring relationship patterns in the source. For example, Sunitinib → Early, If, II, In, JIMT-1, KIT, NSCLC, PDGFR, Phase II, The, VEGFR2 Another extracted example is Sunitinib → An, Before RTKs, However, IFNα, III, In, Objective, Patients, PFS, Renal. Use these groups to spot repeated connection types before inspecting the individual relationships.

Top relations

related to Other solid tumors · 11

Sunitinib → Early, If, II, In, JIMT-1, KIT, NSCLC, PDGFR, Phase II, The, VEGFR2

related to Renal cell carcinoma · 10

Sunitinib → An, Before RTKs, However, IFNα, III, In, Objective, Patients, PFS, Renal

related to Economics · 6

Sunitinib → Doctors, February, Lipitor, November, Pfizer, Sutent

related to Gastrointestinal stromal tumor · 6

Sunitinib → Before, However, III, Imatinib, Like, This

related to Leukemia · 5

Sunitinib → FLT3, His, Louis, St, Washington University

related to Mechanism of action · 5

Sunitinib → PDGF-Rs, RTKs, The, These, VEGFRs

related to Pancreatic neuroendocrine tumors · 4

Sunitinib → European Union, In May, In November, USFDA

Legal status · 3

Sunitinib → AU: S4 (Prescription only), EU: Rx-only, US: ℞-only

has effect · 3

Sunitinib → In, Phase III GIST, The

CAS Number · 2

Sunitinib → 557795-19-4 Y, as salt: 341031-54-7 Y

Important terminology

Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.

Important terminology

patients cell metastatic treatment renal cancer tumors placebo disease adverse carcinoma study ifnα tumor sutent therapy gastrointestinal stromal progression events

Sunitinib relationships Subject–Predicate–Object triples

TTTA extracted 92 structured relationships around Sunitinib. Examples in this analysis include Sunitinib → 3D model (JSmol) → Interactive image and Sunitinib → AHFS/Drugs.com → Monograph. The table shows each extracted connection, where it came from and its confidence.

Subject	Predicate	Object	Confidence	Src
Sunitinib	3D model (JSmol)	Interactive image	1.00	infobox
Sunitinib	AHFS/Drugs.com	Monograph	1.00	infobox
Sunitinib	ATC code	L01EX01 (WHO)	1.00	infobox
Sunitinib	Bioavailability	Unaffected by food	1.00	infobox
Sunitinib	CAS Number	557795-19-4 Y	1.00	infobox
Sunitinib	CAS Number	as salt: 341031-54-7 Y	1.00	infobox
Sunitinib	ChEBI	CHEBI:38940 Y	1.00	infobox
Sunitinib	ChEMBL	ChEMBL535 Y	1.00	infobox
Sunitinib	ChEMBL	as salt: ChEMBL1567	1.00	infobox
Sunitinib	ChemSpider	4486264 Y	1.00	infobox
Sunitinib	ChemSpider	as salt: 4958254	1.00	infobox
Sunitinib	CompTox Dashboard (EPA)	DTXSID1041134	1.00	infobox
Sunitinib	DrugBank	DB01268 Y	1.00	infobox
Sunitinib	DrugBank	as salt: DBSALT000166	1.00	infobox
Sunitinib	Elimination half-life	40 to 60 hours (sunitinib) 80 to 110 hours (metabolite)	1.00	infobox
Sunitinib	Excretion	Fecal (61%) and kidney (16%)	1.00	infobox
Sunitinib	Formula	C22H27FN4O2	1.00	infobox
Sunitinib	IUPHAR/BPS	5713	1.00	infobox
Sunitinib	KEGG	D08552 Y	1.00	infobox
Sunitinib	KEGG	as salt: D06402	1.00	infobox
Sunitinib	Legal status	AU: S4 (Prescription only)	1.00	infobox
Sunitinib	Legal status	US: ℞-only	1.00	infobox
Sunitinib	Legal status	EU: Rx-only	1.00	infobox
Sunitinib	License data	US DailyMed: Sunitinib	1.00	infobox
Sunitinib	MedlinePlus	a607052	1.00	infobox
Sunitinib	Metabolism	Liver (CYP3A4-mediated)	1.00	infobox
Sunitinib	Molar mass	398.482 g·mol−1	1.00	infobox
Sunitinib	Other names	SU11248	1.00	infobox
Sunitinib	Pregnancy category	AU: D	1.00	infobox
Sunitinib	Protein binding	95%	1.00	infobox

Related concept clusters Concept neighborhoods

The concept neighborhoods around Sunitinib bring nearby vocabulary together. In this analysis, examples include Patients, Placebo and Ifnα. Use the clusters to find adjacent concepts and terminology that may deserve separate research.

Sunitinib
- Patients
- Placebo
- Ifnα
- Study
- Tumors
- Metastatic
- Adverse
- Renal
- Cancer
- Cell
- Treatment
- Progression
sunitinib
- Patients
- Placebo
- Ifnα
- Study
- Tumors
- Metastatic
- Adverse
- Renal
- Cancer
- Cell
- Treatment
- Progression
renal cell carcinoma
- Carcinoma
- Renal
- Cell
- Metastatic
- Tumor
- Gastrointestinal
- Stromal
- Treatment
- Cancer
- Kinase
- Tyrosine
- Us
gastrointestinal stromal tumor
- Stromal
- Tumors
- Compared
- Kinase
- Tyrosine
- Treatment
- Tumor
- Significant
- Us
- Disease
- Renal
- Leukemia
renal cancer
- Carcinoma
- Cell
- Metastatic
- Drug
- Treatment
- Study
- Cancer
- Renal
- Gastrointestinal
- Stromal
- Phase
- Treated
metastatic breast cancer
- Renal
- Treatment
- Treated
- Metastatic
- Drug
- Study
- Tumors
- Cell
- Phase
- May
- Significant
- Sunitinib
non-small-cell lung cancer
- Metastatic
- Drug
- Study
- Renal
- Cell
- Phase
- Treated
- Patients
- Sunitinib
- Weeks
- Compared
- May
metastatic
- Renal
- Treatment
- Treated
- Tumors
- May
- Significant
- Sunitinib
- Patients
- Study
- Weeks
- Compared
- Phase

Connections between topic areas Semantic bridges

For Sunitinib, one of the stronger structural bridges in this analysis connects Sunitinib with Mechanism of action. Bridges highlight paths between different parts of the map and can reveal research angles that are easy to miss in a flat list.

Min side: 3

Sunitinib — Mechanism of action · splits 57 ⟂ 16

Sunitinib — Medical uses · splits 58 ⟂ 15

Sunitinib — Overview · splits 61 ⟂ 12

Sunitinib — Research · splits 62 ⟂ 11

Sunitinib — History · splits 65 ⟂ 8

Sunitinib — Society and culture · splits 68 ⟂ 5

Sunitinib — Interactions · splits 70 ⟂ 3

Map overview Semantic statistics

Sunitinib

Nodes73

Edges72

Triples92

Avg. degree1.97

Density0.027397

Components1

Source & methodology

TTTA analyzes the structure around Sunitinib to surface related topics, entities, relationships, concept neighborhoods and bridge connections. Use the map to explore areas such as History, Community, Culture & Applications, including less central topics that may reveal useful research gaps. Automatically extracted connections are research leads rather than rewritten encyclopedia content.

Source: Wikipedia — Sunitinib · EN edition · Analysis: TopicsToTalkAbout